Radiopharmaceutical Production Quality Control Testing Product Stability STOP.

Slides:



Advertisements
Similar presentations
Balancing Redox Equations in Acidic Conditions
Advertisements

Dr. Birgit Schmauser, BfArM, Bonn
Analytical Method Development and Validation
Radiopharmaceutical Production
Radiopharmaceutical Production Filter integrity test STOP.
Using Everyday Equations
Stoichiometry By Danny Chen Andy Wang B (a) According to the equation, how many moles of S 2 O 3 2- are required for analyzing 1.00 mole of O 2.
Radiopharmaceutical Production
Limiting and Excess Reagents
Reconstitution of Solutions Chapter Parts of Solutions.
World Health Organization
AL CHEM REVIEW ORGANIC CHEMISTRY. AL CHEM Written Practical [Organic Chemistry] p.1 ~ Organic Synthesis ~ Organic Acid separate How to separate the product.
Module 12 – part 2 | Slide 1 of 35 January 2006 Basic Principles of GMP Documentation Part 2 15.
Quantitative Fibrinogen Mr. Mohammed A. Jaber.  Fibrinogen assays are quantitative techniques to measure the amount of functional fibrinogen present.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Quality Control of Radiopharmaceuticals
Radionuclide Generators
The effect of concentration on reaction rate
CAPSION. Protect, Enhance, and Save Lives The 1st criteria of differentiation  The formulation ( part 1 )  The addition of ascorbic acid and sodium.
BOHB APCCB LABORATORY USE OF THE ABBOTT MEDISENSE METER FOR BETA-HYDROXYBUTYRATE MEASUREMENT. GRD Jones, A Screnci, P Graham Chemical Pathology,
Quality Control of Radiopharmaceuticals
HIGHER CHEMISTRY REVISION. Unit 1:- Reaction Rates 1. A student was asked to write a plan of the procedure for an investigation. The entry made in her.
Radiopharmaceutical Production
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
Radiopharmaceutical Production Quality Control Testing Visual Inspection STOP.
AICE Biology Lab Review: Biological Molecules & Enzymes
Basic Principles of GMP
Schmitz F., Van Gansbeke B., Monclus M., Van Naemen J., Kadiata M., Ekelmans D., Goldman S. 1 PET/Biomedical Cyclotron Unit, ULB-Hospital Erasme, Route.
International Atomic Energy Agency L 4 PROTECTION ISSUES IN CLINICAL METHODOLOGY.
Chapter 25 Review Solutions. Which of the following particles cannot be stopped by metal foil? a. Alphab. Betac. Gamma.
Radiopharmaceutical Production
Chemistry ( ) Rates of Reaction © SSER Ltd..
CHEMICAL ANALYSIS BY Dr.JAGADEESH. CHEMICAL ANALYSIS RESOLVING A SAMPLE IN TO ITS ULTIMATE COMPONENTS ( COMPOUNDS OR ELEMENTS)
Radiopharmaceutical Production Sub STOP. Radionuclidic purity Radionuclidic purity may be defined as the fraction of total radioactivity that is present.
Fractional Crystallization Problem - I Problem: Sodium sulphate sample contained ammonium sulphate as contaminant Objective: To develop a method.
Name ____________________________________________ Date ______________ Period ____________ Heat Capacity BACKGROUND INFORMATION Heat, as you know by now,
Radiopharmaceutical Production Radionuclidic identity STOP.
Radiopharmaceutical Production
Module 12 - part 2Slide 1 of 23 WHO - EDM Basic Principles of GMP Documentation Part 2 Part One, 14.
Radiopharmaceutical Production
Radiopharmaceutical Production Radioassay STOP. Radiopharmaceutical Production Radioassay Example STOP Radioassay Acceptance Criteria: The product label.
Energy & Chemical Change-_______ is the ability to do ______ or produce _____ I. Potential Energy -__________ energy is the energy of ________, like the.
Measurement Technique A technique was developed for measuring the radioactive concentration of breast milk samples for Tc-99m labelled radiopharmaceuticals.
Preparation and analysis of Cobalt complexes
SEMINAR ON PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM PART DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
7-A Block R III, Johar Town, Lahore, Pakistan SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL & RESEARCH CENTRE References Conclusion.
Introduction Results & Discussion At present, disinfection of wells and drinking water pipelines is carried out by treating with chlorine- containing reagents.
Improved Radiochemical Yields, Reliability and Improvement of Domestic [ 18 F]FDG Auto Synthesizer J. H. PARK, K.S. IM, H.J. Lee, B.C. Lee, I.W Lee Department.
BSB Biomanufacturing CHAPTER 11 GMP – Pharmaceutical Water
Analysis and Design of Beams for Bending
Types of Reactions Pre-Lab
World Health Organization
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
WHO Technical Report Series, No. 953, 2009
EFFECT OF STORAGE TEMPERATURE ON THE STABILITY OF TOTAL PARENTERAL NUTRITION ADMIXTURES PREPARED FOR INFANTS Acta Poloniae Pharmaceutica n Drug Research,
Pictorial Guide To The RCV Procedure
Activated Partial Thromboplastin Time (aPTT)
ОПШТИНА КУРШУМЛИЈА.
Analysis and Design of Beams for Bending
Determination of Cu in Brass
Coagulation Factor Assays
Karl Fischer Titration
Index Notation Sunday, 24 February 2019.
Karl Fischer Titration
HIGHER CHEMISTRY REVISION.
World Health Organization
Reactions in Aqueous Solutions II: Calculations
Radiopharmaceutical Production
Question 2 and Organic chemistry.
Presentation transcript:

Radiopharmaceutical Production Quality Control Testing Product Stability STOP

Product Stability When the activity concentration of [ 18 F]FDG is increased to the hundreds of mCi/mL, [ 18 F]fluoride is the main active product of autoradiolysis and becomes the most important radiochemical impurity. The current US Pharmacopeia (USP) stipulates the minimum radiochemical purity for [ 18 F]FDG as no less than 90% of the total radioactivity assumed to be present at the time of administration to a patient. In contrast, the current European Pharmacopoeia (EP) stipulates the minimum radiochemical purity for [ 18 F]FDG and [ 18 F]FDM as no less than 95% of the total radioactivity of which the [ 18 F]FDM fraction should not exceed 10% of the total radioactivity. Contents Acceptance Criteria Discussion Procedure STOP

Radiopharmaceutical Production QC Testing Product Stability Contents Acceptance Criteria Discussion Procedure STOP Acceptance Criteria Acceptance Criteria: FDG must comply with the requirement for parenteral preparations, and must pass the product stability test. This test needs to be carried out at the highest activity level and smallest volume that would be expected under normal production conditions. Procedure: 200 μL samples of FDG taken within a few minutes of the end of synthesis should be stored at room temperature (22 °C) and aliquots (0.1–5 μL as required to offset decay) can be analysed by radioTLC to monitor the build up of the main decomposition product (free [ 18 F]fluoride) for up to 14 h post synthesis.

Radiopharmaceutical Production QC Testing Product Stability Contents Acceptance Criteria Discussion Procedure STOP Discussion Discussion: The product must be validated using this test and revalidated on a periodic basis or whenever the procedure of synthesis is changed or there is an increase in yield so that the activity per unit volume is increased. To study the impact of stabilisers, samples of FDG (50–100 μL) can be treated with reagents to the concentrations shown and both treated and untreated FDG samples subjected to a room temperature stability study. Separate stability studies ned to be performed to observe the effect of (i) radioactive concentration, (ii) added ethanol, (iii) added hydrogen peroxide, (iv) added ascorbic acid, (v) added sodium nitrite, (vi) added sodium thiosulfate and (vii) added sodium iodide upon the decomposition of FDG.

Radiopharmaceutical Production QC Testing Product Stability Contents Acceptance Criteria Discussion Procedure STOP Stability Procedure A plot of the amount of fluoride present in the sample should be generated to show that the purity of the FDG remains with the acceptance limits during the normal lifetime of the FDG. Link to Demonstration (UNDER CONSTRUCTION)

Return to Main Menu